{'fraction_non_alphanumeric': 0.019201228878648235, 'fraction_numerical': 0.0038402457757296467, 'mean_word_length': 5.786458333333333, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Hereditary Hemorrhagic Telangiectasia: Update on Screening, Diagnosis, and Management

Hereditary hemorrhagic telangiectasia (HHT) or Osler-Weber-Rendu syndrome is an inherited angiodysplasia through autosomal dominance that is underrecognized as well as underdiagnosed in the general population. It has an estimated prevalence of at least 1 in 5000 individuals and displays an age-dependent penetrance along with a variable clinical presentation, even within family members with identical mutations. It most commonly manifests with the presence of telangiectasias of the skin and the nose, and is frequently complicated by the presence of arteriovenous malformations and telangiectasias in the brain, lungs, gastrointestinal tract, and liver. These internal manifestations can often be silent and lead to life-threatening complications of stroke and hemorrhage. Medical care for patients with HHT is improving today due to greater understanding of causative genetics and disease pathobiology as well as the establishment of dedicated HHT centers that, through a multidisciplinary approach, screen for and treat the various manifestations of this disorder. The purpose of this review is to go over the diagnosis of HHT, prevention of disease-related complications, and treatment of symptomatic disease.